Form 144 INSMED Inc Filed by: Flammer Martina M.D.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
BofA Securities Reiterates Buy Rating on Insmed (INSM); 'pullback overdone'
May 12, 2026 12:02 PM EDTBofA Securities analyst Jason Zemansky reiterated a Buy rating and $214.00 price target on Insmed (NASDAQ: INSM) saying the Brinsupri launch momentum is solid and the pullback in the stock is overdone.
The analyst commented, "We hosted Insmed at an investor dinner last night... More
